# United Therapeutics Corporation (UTHR) FY2026 Q2 P&L / Income Statement

- Company: United Therapeutics Corporation (UTHR)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001082554-26-000027
- Page: https://plicit.ai/financials/uthr/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/uthr-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue and costs use their disclosed categories.

- **Total revenues**: 783,300,000 US dollars
- **Cost of sales**: 99,500,000 US dollars
- **Gross profit (calculated)**: 683,800,000 US dollars
- **Operating expenses (calculated)**: 353,000,000 US dollars
- **Operating income**: 330,800,000 US dollars
- **Total other income, net**: 41,900,000 US dollars
- **Income before income taxes**: 372,700,000 US dollars
- **Income tax expense**: 39,700,000 US dollars
- **Net income**: 333,000,000 US dollars
- **Remodulin revenue**: 126,300,000 US dollars
- **Orenitram revenue**: 125,700,000 US dollars
- **Unituxin revenue**: 65,200,000 US dollars
- **Adcirca revenue**: 6,700,000 US dollars
- **Other revenue**: 6,800,000 US dollars
- **Tyvaso DPI revenue**: 326,600,000 US dollars
- **Nebulized Tyvaso revenue**: 126,000,000 US dollars
- **Remodulin cost of revenue**: 17,400,000 US dollars
- **Orenitram cost of revenue**: 6,100,000 US dollars
- **Unituxin cost of revenue**: 2,000,000 US dollars
- **Adcirca cost of revenue**: 3,000,000 US dollars
- **Other cost of revenue**: 11,000,000 US dollars
- **Tyvaso DPI cost of revenue**: 51,100,000 US dollars
- **Nebulized Tyvaso cost of revenue**: 8,900,000 US dollars
- **Research and development**: 146,300,000 US dollars
- **Selling, general, and administrative**: 206,700,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Geography

- Page: https://plicit.ai/financials/uthr/fy2026-q2-income-statement/revenue-by-geography
- Chart image: https://plicit.ai/charts/uthr-fy2026-q2-revenue-by-geography-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 783,300,000 US dollars
- **Cost of sales**: 99,500,000 US dollars
- **Gross profit (calculated)**: 683,800,000 US dollars
- **Operating expenses (calculated)**: 353,000,000 US dollars
- **Operating income**: 330,800,000 US dollars
- **Total other income, net**: 41,900,000 US dollars
- **Income before income taxes**: 372,700,000 US dollars
- **Income tax expense**: 39,700,000 US dollars
- **Net income**: 333,000,000 US dollars
- **UNITED STATES**: 733,600,000 US dollars
- **Non-US**: 49,700,000 US dollars
- **Research and development**: 146,300,000 US dollars
- **Selling, general, and administrative**: 206,700,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.